Research on a new kind of cannabis treatment prepares to move forward.
Cannabis is gaining wider acceptance as a therapeutic for mental health issues. California-based Royal Emerald Pharmaceuticals is currently pursing Federal Drug Administration approval to research, develop, and manufacture medicines derived from cannabidiol (CBD) and tetrahydroncannabinol (THC).
In this Mental Health Minute, founder and CEO of Royal Emerald Pharmaceuticals Mark Crozier reveals the motivation behind his quest to make non-addictive medicines for PTSD, pain, anxiety, depression, opiate addiction, and other conditions.
Mr Crozier is the Founder and CEO of Royal Emerald Pharmaceuticals. Crozier has 40 years of experience in the military and law enforcement with the bulk his career was spent in criminal intelligence. He is a former Army Ranger and a retired federal police chief.
Would you prescribe non-addictive cannabis treatments? Share comments with your colleagues by emailing PTEditor@mmhgroup.com. Comments may be shared online pending review and editing for style.